Publications du CIC-P 0203 (2016)


<^>Articles rattachés à des protocoles

Articles rattachés à des protocoles :

Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial. Annane D, Brun-Buisson C, Cariou A, Martin C, Misset B, Renault A, Lehmann B, Millul V, Maxime V, Bellissant E; APROCCHSS Investigators for the TRIGGERSEP Network.. Ann Intensive Care. 2016 Dec;6(1):79. doi: 10.1186/s13613-016-0165-1. Epub 2016 Aug 19. No abstract available
Protocole : Aprocchs
Nalmefene for alcohol dependence: a NICE decision? Naudet F, Fitzgerald N, Braillon A. Lancet Psychiatry. 2016 Dec;3(12):1104-1105. doi: 10.1016/S2215-0366(16)30356-X. No abstract available.
Protocole : Nalmefene DPSYDMETA
HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. Grégoire M, Tadié JM, Uhel F, Gacouin A, Piau C, Bone N, Le Tulzo Y, Abraham E, Tarte K, Zmijewski JW. J Leukoc Biol. 2016 Dec 13. pii: jlb.5HI0316-128RR. [Epub ahead of print]
Protocole : HMGB1
Pharmacokinetics of oral fludrocortisone in septic shock. Polito A, Hamitouche N, Ribot M, Polito A, Laviolle B, Bellissant E, Annane D, Alvarez JC. Br J Clin Pharmacol. 2016 Dec;82(6):1509-1516. doi: 10.1111/bcp.13065. Epub 2016 Aug 22.
Protocole : Fludro Choc
Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosis. Hamdi-Rozé H, Beaumont-Epinette MP, Ben Ali Z, Le Lan C, Loustaud-Ratti V, Causse X, Loreal O, Deugnier Y, Brissot P, Jouanolle AM, Bardou-Jacquet E. Am J Hematol. 2016 Dec;91(12):1202-1205. doi: 10.1002/ajh.24535.
Protocole : Logifer
Variations of hepcidin and iron-status parameters during the menstrual cycle in healthy women. Lainé F, Angeli A, Ropert M, Jezequel C, Bardou-Jacquet E, Deugnier Y, Gissot V, Lacut K, Sacher-Huvelin S, Lavenu A, Laviolle B, Comets E. Br J Haematol. 2016 Dec;175(5):980-982. doi: 10.1111/bjh.13906
Protocole : Hepmen
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Azzouzi AR1, Vincendeau S2, Barret E3, Cicco A4, Kleinclauss F5, van der Poel HG6, Stief CG7, Rassweiler J8, Salomon G9, Solsona E10, Alcaraz A11, Tammela TT12, Rosario DJ13, Gomez-Veiga F14, Ahlgren G15, Benzaghou F16, Gaillac B16, Amzal B17, Debruyne FM18, Fromont G19, Gratzke C7, Emberton M20; PCM301 Study Group. Lancet Oncol. 2016 Dec 19. pii: S1470-2045(16)30661-1. doi: 10.1016/S1470-2045(16)30661-1. [Epub ahead of print]
Protocole : PCM301
Melatonin: pharmacology, functions and therapeutic benefits. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C. Curr Neuropharmacol. 2016 Dec 28. [Epub ahead of print]
Protocole : Meladose
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin? Naudet F. Pharmacopsychiatry. 2016 Nov;49(6):260-261. Epub 2016 Jul 7. No abstract available.
Protocole : DPSYDMETA
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, Lavoué S, Vérin M, Gauvrit JY, Le Tulzo Y, Edan G. N Engl J Med. 2016 Nov 3;375(18):1717-1725.
Protocole : BIA 10-2474
Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study. Braquet P1, Alla F2, Cornu C3, Goehringer F4, Piroth L5, Chirouze C6, Revest M7, Lechiche C8, Duval X9, Le Moing V10; VIRSTA-AEPEI study group. Clin Microbiol Infect. 2016 Nov;22(11):948.e1-948.e7. doi: 10.1016/j.cmi.2016.07.034.
Protocole : Virsta
The structure, organisation and perioperative management of ambulatory surgery and anaesthesia in France: Methodology of the SFAR-OPERA study. Albaladejo P, Aubrun F, Samama CM, Jouffroy L, Beaussier M, Benhamou D, Romegoux P, Skaare K, Bosson JL, Ecoffey C. Anaesth Crit Care Pain Med. 2016 Nov 29. pii: S2352-5568(16)30221-1. doi: 10.1016/j.accpm.2016.10.002. [Epub ahead of print]
Protocole : Opera
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hébuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S; GETAID.. J Crohns Colitis. 2016 Oct;10(10):1179-85. doi: 10.1093/ecco-jcc/jjw129. Epub 2016 Jul 11.
Protocole : DPSYDMETA
ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC., Group BS. Antivir Ther. 2016 Sep 1. doi: 10.3851/IMP3074. [Epub ahead of print]
Protocole : Boceprevih
Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy? Naudet F, Granger B, Braillon A. Alcohol Alcohol. 2016 Sep;51(5):623-4. doi: 10.1093/alcalc/agw029. Epub 2016 Jun 3. No abstract available.
Protocole : DPSYDMETA
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups.. AIDS. 2016 Aug 24;30(13):2085-90. doi: 10.1097/QAD.0000000000001143
Protocole : Boceprevih
Evaluation in alcohol use disorders - insights from the nalmefene experience. Naudet F, Palpacuer C, Boussageon R, Laviolle B. BMC Med. 2016 Aug 18;14(1):119. doi: 10.1186/s12916-016-0664-9.
Protocole : Nalmefene
Exploring psychic transparency during pregnancy: a mixed-methods approach. Oriol C, Tordjman S, Dayan J, Poulain P, Rosenblum O, Falissard B, Dindoyal A, Naudet F. BMC Womens Health. 2016 Aug 12;16(1):55. doi: 10.1186/s12905-016-0332-4.
Protocole : DPSYDMETA
Early diagnosis of NAFLD-NASH transition using mid infrared spectroscopy. NASHFIBRE Bensaid S, Kachenoura A, Costet N, De Ledinghen V, Vergniol J, Laine F, Turlin B, Tariel H, Senhadji L. Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:3602-3605. doi: 10.1109/EMBC.2016.7591507.
Protocole : Nashfibre
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G, Godmer P, Bouabdallah K, Milpied N, Damaj G, Tarte K, Fest T, Roussel M. Blood. 2016 Aug 25;128(8):1081-92. doi: 10.1182/blood-2015-08-662783. Epub 2016 Jun 23.
Protocole : Imprim
Colonic anastomoses and non-steroidal anti-inflammatory drugs. Slim K, Joris J, Beloeil H; Groupe Francophone de Réhabilitation Améliorée après Chirurgie (GRACE).. J Visc Surg. 2016 Aug;153(4):269-75. doi: 10.1016/j.jviscsurg.2016.06.011. Epub 2016 Jul 29.
Protocole : GRACE
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. J Crohns Colitis. 2016 Jul;10(7):812-20. doi: 10.1093/ecco-jcc/jjw032. Epub 2016 Jan 27.
Protocole : ART
The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. Tubiana S1, Duval X2, Alla F3, Selton-Suty C4, Tattevin P5, Delahaye F6, Piroth L7, Chirouze C8, Lavigne JP9, Erpelding ML10, Hoen B11, Vandenesch F12, Iung B13, Le Moing V14; VIRSTA/AEPEI Study Group. J Infect. 2016 May;72(5):544-53. doi: 10.1016/j.jinf.2016.02.003. Epub 2016 Feb 22.
Protocole : Virsta